Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5532 - Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Pathology/Molecular Biology;  Breast Cancer

Presenters

Peter A. Fasching

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

P.A. Fasching1, M. Laible2, K.E. Weber3, R.M. Wirtz4, C. Denkert5, K. Schlombs6, S. Schmatloch7, O. Camara8, H.J. Lück9, J. Huober10, T. Karn11, M.T. van Mackelenbergh12, F. Marme13, V. Müller14, C. Schem15, E. Stickeler16, U. Sahin17, S. Loibl18, M. Untch19

Author affiliations

  • 1 Department Of Gynecology And Obstetrics, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 2 Gynäkologie, BioNTech Diagnostics GmbH, Mainz/DE
  • 3 Statistic, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg/DE
  • 4 Stratifyer Molecular Pathology Gmbh, STRATIFYER Molecular Pathology GmbH, 50935 - Cologne/DE
  • 5 Institute Of Pathology, Charite Berlin Mitte, 10117 - Berlin/DE
  • 6 Biontech Diagnostics Gmbh, BioNTech Diagnostics GmbH, Mainz/DE
  • 7 Brustzentrum, Elisabeth Krankenhaus, Kassel/DE
  • 8 Brustzentrum, Hufeland Klinikum, Bad Langensalza/DE
  • 9 Gynäkologie, Gynäkologisch-Onkologische Praxis, Hannover/DE
  • 10 Gynecol. & Obstetrics, Universitaetsfrauenklinik Ulm, 89075 - Ulm/DE
  • 11 Klinik Für Frauenheilkunde Und Geburtshilfe, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), 60590 - Frankfurt am Main/DE
  • 12 Clinic For Gynecology And Obstetrics, University Hospital Schleswig-Holstein, Kiel/DE
  • 13 Gynecologic Oncology, Nationales Zentrum für Tumorerkrankungen (NCT), 69120 - Heidelberg/DE
  • 14 Department Of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg/DE
  • 15 Mammazentrum Hamburg, Hospital Jerusalem, Hamburg/DE
  • 16 Gynäkologie Und Geburtsmedizin, Uniklinik RWTH, Aachen/DE
  • 17 Management, BioNTech AG, 55131 - Mainz/DE
  • 18 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 19 Gynäkologie Und Geburtshilfe, Helios Klinikum Berlin-Buch, 0000 - Berlin/DE
More

Resources

Abstract 5532

Background

Prediction of the response to NACT in early BC patients (pts) can lead to improved treatment decisions. The MammaTyper® test can be used to predict the probability of pCR after NACT by integrating accurate and reproducible assessment of ERBB2, ESR1, PGR and MKI67 mRNA into a standardized prediction model (Varga et al. Breast Cancer Research 2017).

Methods

Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples of pts with cT1-2 BC enrolled in in the single arm phase II TECHNO trial (Untch et al. JCO 2011) and the randomised phase III PREPARE trial (Untch et al. Ann Oncol. 2011). MammaTyper®, a molecular in vitro diagnostic RT-qPCR test, was used to assess the expression of ERBB2 (HER2), ESR1 (ER), PGR (PR) and MKI67 (Ki67) genes from which a predefined continuous score was calculated. The study aimed to validate the MammaTyper® pCR-score for predicting pCR (ypT0 ypN0) after NACT in BC. Pts were classifed into a low or high score group according to a predefined cutoff: score ≤41 predicts a low probability of pCR; score ≥42 predicts a high pCR rate.

Results

A total of 324 pts with available FFPE samples and MammaTyper® measurements were analyzed. The MammaTyper® score was significantly associated with an increased pCR rate (AUC=0.805, p < 0.001). Similarly, pts with high MammaTyper® score (N = 159) had more frequently pCR compared to pts with low score (N = 165) (30.2% vs 3.0%, respectively; OR = 13.84 [95%CI 5.34-35.86], p < 0.001). In addition, the MammaTyper® pCR-score remained significantly predicitve when adjusted for age, nodal status, tumor grade and treatment (OR = 10.90 [95%CI 3.38-35.16], p < 0.001). Within the non-pCR subgroup, pts with low score had a significantly longer disease-free (DFS) and overall (OS) survival compared to pts with high score (DFS HR = 1.59, 95%-CI 1.04-2.44, p = 0.032; OS HR = 2.85, 95%-CI 1.62-5.00, p < 0.001).

Conclusions

The MammaTyper® pCR-score predicts pCR after NACT and seems to improve prognosis additionally to clinical predictors in pts with early BC. Its utility with regard to conventional ER, PR, Ki67 and HER2 has to be analyzed in future studies.

Clinical trial identification

Legal entity responsible for the study

GBG Forschungs GmbH and BioNTech Diagnostics GmbH, Mainz.

Funding

BioNTech Diagnostics GmbH, Mainz, Germany.

Editorial Acknowledgement

Disclosure

P.A. Fasching: Personal fees: Celgene, during the conduct of the study; Grants and personal fees: Novartis; Personal fees: Pfizer, Roche, Teva, outside the submitted work. M. Laible: Personal fees: BioNTech Diagnostics GmbH, outside the submitted work; Employee: BioNTech Diagnostics GmbH); Patent WO 2015/024942 pending, new patent application pending. K.E. Weber: Grants and non-financial support: BioNTech Diagnostics GmbH, Mainz, Germany, during the conduct of the study; Patent EndoPredict issued. C. Denkert: Personal fees: Teva, Novartis, Pfizer, Roche, Amgen, MSD Oncology; Other: Sividon Diagnostics, outside the submitted work. K. Schlombs: Personal fees: BioNTech Diagnostics GmbH, outside the submitted work; Patent WO 2015/024942 pending; New patent application pending. F. Marme: Personal fees; Roche, AstraZeneca, Pfizer, Tesaro, Novartis, Amgen, PharmaMar, GenomicHealth, CureVac, Eisai, outside the submitted work. S. Loibl: Grants: AbbVie, Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Teva, Vifor during the conduct of the study and outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.